| A Randomized, Double-blind, Placebo-controlled Phase 3 Study to evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Participants with Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma (JADE) |
Ongoing |
Dostarlimab (GSK4057190) |
3 |
221530 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A 2-Part, Open-Label, Phase 2, Multiple Dose Study to Evaluate the Pharmacodynamic Effects, Safety, and Tolerability of Patiromer in Children under 12 Years of Age with Hyperkalaemia (EMERALD2) |
Ongoing |
Patiromer |
2 |
RLY5016-208p |
King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Riyadh), King Saud University Medical City (Riyadh) |
| A Phase 2 Study for the Treatment of Anemia with Alpha (α)-Thalassemia to Determine the Efficacy and Safety of Luspatercept (BMS-986346/ACE-536) in Adults and Evaluate the Safety and Pharmacokinetics in Adolescents |
Ongoing |
Luspatercept |
2 |
CA056015 |
King Khalid University Hospital (Riyadh) |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of Povetacicept In Adults With Immunoglobulin A Nephropathy (Rainier) |
Ongoing |
Povetacicept |
3 |
AIS-D08 |
King Saud University Medical City (Riyadh), King Fahad Specialist Hospital (Dammam), King Faisal Specialist Hospital and Research Center (Jeddah), King Abdulaziz Medical City NG (Riyadh) |
| Impact of an Oxygen-Loaded Sustained-Release Hyaluronic Acid Hydrogel on Periodontal Pocket Depth Reduction and Pain Control: A Split-Mouth Randomized Clinical Trial |
Ongoing |
Hyaluronic acid and Oxygel gel |
4 |
OHGel2025 |
Dental Hospital of King Khalid University (Abha) |
| A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis |
Ongoing |
Survodutide |
3 |
1404-0064 |
King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Phase 2, adaptive, randomized, open-label, assessor-blinded active-controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus Standard of Care in patients suffering from systemic lupus erythematosus (SLE) with active, refractory lupus nephritis (LN) |
Ongoing |
Rapcabtagene autoleucel (YTB323) |
2 |
CYTB323J12201 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| An Open-Label, Multi-Centre, Rollover Study to Characterise Long-Term Safety and Efficacy of Etavopivat In Adults, Adolescents and Children Who Have Sickle Cell Disease or Thalassaemia And Have Completed A Treatment Period in An Etavopivat Study |
Ongoing |
Etavopivat |
3 |
NN7535-7822 |
Prince Mohammad Bin Naser Hospital (Jazan) |
| Phase 2, randomized, open-label, controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe refractory idiopathic inflammatory myopathies |
Ongoing |
Rapcabtagene autoleucel (YTB323) |
2 |
CYTB323L12201 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| EASi-HF reduced – A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% |
Ongoing |
Vicadrostat (BI 690517)/ Jardiance (BI 10773) |
3 |
1378-0018 |
King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Medical City (Riyadh) |
